Gamida Cell Ltd (NASDAQ:GMDA)
| 1.66 Delayed Data As of Feb 02 |  +0.01 / +0.61%Today’s Change | 1.10 Today|||52-Week Range 4.72 | +28.68% Year-to-Date |
| SECTOR Health Technology | INDUSTRY Pharmaceuticals: Major | MARKET CAP $120.8M |
Company Description
Gamida Cell Ltd. engages in the development of cell therapies to cure blood cancer and rare serious hematologic diseases. The firm offers Omidubicel, an investigational product with potential as a life-saving alternative for patients in need of a bone marrow transplant, and a line of modified and unmodified nicotinamide-enabled natural killer cells targeted at solid tumor and hematological malignancies. The company was founded by Tony Peled and Menashe Levy in 1998 and is headquartered in Boston, MA.
Contact Information
Gamida Cell Ltd. 116 Huntington Avenue Boston Massachusetts 02116 |
Employees
Shareholders
| Other institutional | 19.13% |
| Mutual fund holders | 13.58% |
| Individual stakeholders | 1.15% |
Top Executives
| Abigail L. Jenkins | President, Chief Executive Officer & Director |
| Michele I. Korfin | Chief Operating & Commercial Officer |
| Shai Lankry | Chief Financial Officer |
| Ronit Simantov | Chief Medical & Scientific Officer |
| Yona Geffen | Vice President-Research & Development |
